Biomedical subjects
Publications and source records attributed to M Baryalei.
We present a case of severe accidental hypothermia (core temperature 22 degrees C) after a suicide attempt. The initial symptoms and the pre-hospital and hospital treatment are discussed. Additionally, different rewarming strategies for patients with severe accidental hypothermia are compared.
BACKGROUND: We evaluated cyclosporine (CSA) dose reduction and mycophenolate mofetil (MMF) treatment versus maintained CSA dosage and azathioprine (AZA) in HTX regarding renal function and safety from CSA nephrotoxicity (creatinine > 1.7 mg/dL). METHODS: Fourteen recipients (group 1: 12 men, 2 women) with CSA-based immunosuppression (plus azathioprine and/or steroids) were started on 2000 mg MMF/d. Azathioprine was discontinued and CSA tapered to trough whole blood levels of 70 to 120 microg/L. Ten recipients (group 2: seven men, three women) were maintained on their CSA dosages. Creatinine clearance, serum creatinine, uric acid, urea nitrogen, and rejection were monitored. RESULTS: Mean age was 58 (range 44 to 69 years) and 48 years (range 24 to 61 years) in groups 1 and 2, respectively. In group 1 creatinine fell from 2.7 +/- 0.8 to 1.9 +/- 0.5 mg/dL (baseline vs control 2: P =.001); uric acid and urea nitrogen remained constant. CSA levels decreased from 173 +/- 56 to 110 +/- 33 microg/L (P =.02). In group 2 creatinine (2.4 +/- 0.7 vs 2.3 +/- 0.5 mg/dL), uric acid, urea nitrogen, and CSA levels remained constant. Comparison between groups showed higher creatinine clearance (50 +/- 18 vs 29 +/- 14 mL/min; group 1 vs group 2: P =.02), lower CSA levels (110 +/- 33 vs 161 +/- 35 microg/L; P <.001) and a trend toward lower serum creatinine (1.9 +/- 0.5 vs 2.3 +/- 0.5 mg/dL, P =.077). There were two rejections >/= 1B according to ISHLT in the study and four in the control group. Two deaths occurred in each group. CONCLUSIONS: Conversion from AZA to MMF after CSA reduction improves creatinine clearance in HTX recipients and reduces serum creatinine. No negative effect on patient safety was identified by rejection rate or survival.
BACKGROUND: Cyclosporine (CsA) nephrotoxicity is a common problem after cardiac transplantation. We have studied the impact of CsA dose reduction in association with mycophenolate mofetil (MMF) treatment on renal function in heart transplant recipients with suspected CsA nephrotoxicity (serum creatinine level >2 mg/dl). METHODS: Twelve heart transplant recipients (11 men, 1 woman; 111 to 1813 days after transplantation) with CsA-based immunosuppression (plus azathioprine and/or steroids) and a serum creatinine level >2.0 mg/dl were started on a daily dose of 2000 mg of MMF. Dilated cardiomyopathy was the underlying disease in nine patients, ischemic cardiomyopathy in three patients. Mean patient age was 57 years (range 44-69 years). Azathioprine was discontinued and CsA slowly tapered. Creatinine clearance, serum creatinine level, urea nitrogen, and uric acid were monitored. CsA levels were measured, and CsA dose was adjusted for whole blood levels of 70-120 microg/L. Ten patients still had endomyocardial biopsies, whereas one had echocardiographic controls only. RESULTS: One grade 1B rejection episode according to ISHLT (International Society for Heart and Lung Transplantation) was observed until 1 year after the switch to MMF. One patient was excluded due to gastrointestinal side effects. CONCLUSIONS: Conversion from azathioprine to MMF with consecutive reduction of CsA in heart transplant recipients with CsA-impaired renal function improves renal function as evidenced by lower serum creatinine, urea nitrogen, uric acid, and higher creatinine clearance.
Physiologically, human atrial and ventricular myocardium are coupled by an identical beating rate and rhythm. However, contractile behavior in atrial myocardium may be different from that in ventricular myocardium, and little is known about intracellular Ca(2+) handling in human atrium under physiological conditions. We used rapid cooling contractures (RCCs) to assess sarcoplasmic reticulum (SR) Ca(2+) content and the photoprotein aequorin to assess intracellular Ca(2+) transients in atrial and ventricular muscle strips isolated from nonfailing human hearts. In atrial myocardium (n = 19), isometric twitch force frequency dependently (0. 25-3 Hz) increased by 78 +/- 25% (at 3 Hz; P < 0.05). In parallel, aequorin light signals increased by 111 +/- 57% (P < 0.05) and RCC amplitudes by 49 +/- 13% (P < 0.05). Similar results were obtained in ventricular myocardium (n = 13). SR Ca(2+) uptake (relative to Na(+)/Ca(2+) exchange) frequency dependently increased in atrial and ventricular myocardium (P < 0.05). With increasing rest intervals (1-240 s), atrial myocardium (n = 7) exhibited a parallel decrease in postrest twitch force (at 240 s by 68 +/- 5%, P < 0.05) and RCCs (by 49 +/- 10%, P < 0.05). In contrast, postrest twitch force and RCCs significantly increased in ventricular myocardium (n = 6). We conclude that in human atrial and ventricular myocardium the positive force-frequency relation results from increased SR Ca(2+) turnover. In contrast, rest intervals in atrial myocardium are associated with depressed contractility and intracellular Ca(2+) handling, which may be due to rest-dependent SR Ca(2+) loss (Ca(2+) leak) and subsequent Ca(2+) extrusion via Na(+)/Ca(2+) exchange. Therefore, the influence of rate and rhythm on mechanical performance is not uniform in atrial and ventricular myocardium.
The present study aimed at investigating the influence of fixation methods on the ultrastructure and calcium content of five different aortic biovalves. Biovalves subcutaneously implanted in Wistar rats for 12 weeks demonstrated significant differences in their calcium contents. Using Scheffe tests, two different groups of biovalves could be distinguished: (i) valves with high calcium content, such as Toronto-SPV (165 +/- 42 mg/g dry tissue) and Intact (193 +/- 36 mg/g dry tissue), and (ii) valves with low calcium content, such as Mosaic (2.7 +/- 1.8 mg/g dry tissue), Freestyle (2.3 +/- 1.1 mg/g dry tissue) and Hancock-II (3.6 +/- 1.2 mg/g dry tissue) (P < 0.05). All biovalves with an ultrastructurally preserved endothelium exhibited a low calcification tendency. The data suggest that if the endothelium is lost as a result of the fixation procedure, then calcification can only be prevented by appropriate anticalcification methods.
The Toronto SPV bioprosthesis for aortic valve replacement has been prospectively evaluated in 100 patients, since March 1993. Intraoperative transoesophageal and postoperative transthoracic echocardiography were used to assess valve function. Follow-up was complete in 74 patients at 6 months and in 38 patients at 1 year. The average valve size implanted was 26.5 mm. Some 37 patients had additional coronary artery bypass grafting surgery. The hospital mortality rate was 4%. Non-structural valve dysfunction occurred in one patient and late endocarditis in another patient required operation. There were no other valve complications. None of the patients developed clinically relevant aortic valve incompetence during follow-up and there was a significant decrease in pressure gradients, increase in valve orifice areas and decrease in left ventricular hypertrophy.
BACKGROUND AND AIMS OF THE STUDY: Despite a variety of different artificial heart valves no ideal prosthesis for the small aortic root is yet available. Conventional stented valves are hemodynamically disadvantageous because of higher transvalvular pressure gradients. Stentless bioprostheses were implanted in such patients to evaluate their performance as an alternative to homografts and to conventional mechanical prostheses. MATERIALS AND METHODS: We analyzed 57 patients with small aortic roots who underwent stentless aortic valve replacement (Toronto SPV) from March 1993 to November 1995. All but two patients had aortic stenosis. The mean age at operation was 70.9 (+/-8.2) years. The annular diameter was 18-23 mm (mean 21.4 +/- 1.1 mm) in all patients. Of the 57 patients, 17 received a 23 mm and 40 patients a 25 mm prosthesis. RESULTS: Using the oversizing technique, valve size was adjusted according to the sinotubular junction diameter, allowing a gain in prosthesis size of 2-4 mm to be achieved in all patients. On pre-discharge echocardiography maximum flow velocity was 2.3 +/- 0.4 m/s, maximum pressure gradient was 19.1 +/- 6.8 mmHg, and effective valve orifice area was 1.46 +/- 0.27 cm2. All patients were in NYHA class I or II at discharge. One patient was reoperated due to a folded annulus caused by too much oversizing. At six months follow up there was a significant reduction in pressure gradients and an increase in effective valve orifice areas in relation to a decrease in pre-existing left ventricular hypertrophy. CONCLUSIONS: Stentless bioprostheses show excellent hemodynamics due to their comparably large internal diameter and flexibility. Controlled oversizing is a safe technique without additional complications. As larger valve sizes can be implanted, aortic root enlargement is not necessary. The superior hemodynamic profile of stentless aortic valves is especially advantageous in patients with small aortic roots.
Stentless valves may be an alternative to conventional stented bioprostheses and homografts. From all tissue valves homografts proved to have the best long term results. But homografts are not always available. Stentless bioprostheses are similar to homografts concerning in implantation technique, valve anatomy and physiologic function. The stentless design leads to remodeling of the left ventricle and the aortic root, resulting in a superior hemodynamic profile. Nevertheless long term results are required.
A 45-year-old male with end-stage dilative cardiomyopathy was referred for heart transplantation (HTx). Apart from severe heart disease the patient had an unremarkable medical history. Risk factors were heavy smoking and moderate consumption of alcohol. Preoperative screening including a thorough ENT status did not reveal any other risk factor or contraindication for heart transplantation. HTx was performed three months later. Immunosuppressive therapy consisted of triple-drug therapy and induction therapy with antithymocyte globulin. The patient had an uneventful perioperative course. One month after transplantation the patient developed a rapidly growing squamous cell carcinoma of the left tonsil with local metastasis. Because of the rapid growth and size of the tumor surgical treatment was already impossible at that early time. Despite a course of chemotherapy the tumor continued to grow; treatment was changed to radiation therapy resulting in partial remission. Cyclosporine and azathioprine dosages were reduced at the same time. 9 months following HTx the patient developed a rapidly growing recurrence. As there were no further therapeutic options, immunosuppressive therapy was completely discontinued with the patient's agreement. He died 2 months later. The rapid tumor growth and its early manifestation following HTx suggest a preexistent occult carcinoma. A more extensive and repetitive preoperative screening in HTx candidates who are heavy smokers should be considered.
BACKGROUND: We studied the long-term results of heart valve replacement with the Toronto SPV bioprosthesis. METHODS: From March 1993 until July 1994 the Toronto stentless bioprosthesis was implanted in 100 selected patients with a mean age of 70.7 years. The predominant aortic valve lesion was stenosis in 94 and insufficiency in 6 cases. Eighty-eight patients received a valve 25 mm in diameter or larger. Additional coronary artery bypass grafting was performed in 37 cases. Hospital mortality was 4%. Seventy-four patients were seen at 6 months and 38 patients at 1 year follow-up. RESULTS: Structural deterioration, thromboembolism or hemorrhage were not encountered. Nonstructural dysfunction lead to reoperation in 1 patient. Another patient presented with endocarditis at 1 year postoperatively. There were no other valve-related complications. Echocardiographic mean pressure gradients ranged from 7.7 to 11.1 mm Hg postoperatively. There was a significant decrease in pressure gradients at 6 months of follow-up. Minimal aortic valve incompetence was seen in 3 patients. CONCLUSIONS: The Toronto stentless bioprosthesis has superior hemodynamics and is an excellent alternative to conventional stented bioprostheses. Long-term evaluation has to prove whether this promising new valve can live up to its expectations.
Since March 1993 the Toronto SPVTM bioprosthesis has been implanted in 100 patients. Our prospective study evaluated the echocardiographic valve characteristics and the influence of the echocardiographic assessment on surgical technique. Transesophageal echocardiography (TEE) was applied before and during surgery, and transthoracic echocardiography (TTE) postoperatively. The average valve size implanted was 26.5 mm. Follow up was complete in 74 patients at six months and in 38 patients at one year. Pre-cardiopulmonary bypass (CPB) TEE valve sizing was accurate by +/- 1 mm in 81 patients as compared to mechanical sizing. Post-CPB valve closure was concentric in 99 patients. Minimal aortic incompetence was present in seven patients at one week, in two patients at six months and in one patient at one year. Mean pressure gradients ranged from 7.7 to 11.1 mmHg postoperatively. Overall mortality was 4%. One patient with non-structural dysfunction and another with endocarditis at one year postoperatively were reoperated successfully. At follow up there was a significant decrease in transvalvular pressure gradients and an increase in valve orifice areas. In 32 patients a decrease in left ventricular posterior wall (LVPW) hypertrophy was found (p < 0.001). There was a decrease in tissue depth and recurrence of the dynamic movement of the aortic root. It is concluded that TEE valve sizing is reliable for early valve selection. Valve incompetence is not a clinically relevant issue using the oversizing technique. Improved hemodynamics at follow up can be explained by remodeling of the aortic root and by a decrease in left ventricular hypertrophy. The excellent hemodynamic profile, resembling native aortic valve function, is impressive and has to be confirmed by long term evaluation.
Strut fractures followed by disk escape of Björk-Shiley convexo-concave valve prostheses are a well-known problem. This article discusses the case of a successfully treated patient who was admitted to our institution with extreme and prolonged cardiogenic shock. The strut was dislodged into the main stem of the left coronary artery and the disk into the iuxtarenal abdominal aorta. The intent of this report is, in particular, to illustrate the management problems. Immediately after diagnosis, circulation and oxygenation were ensured by use of a portable cardiopulmonary bypass support (CPS) system whose circulation lines were introduced subcutaneously. Thus the transfer to the operating room and the surgical intervention were able to start under controlled conditions. The disk was removed by Fogarty catheter manoevre without any problems during the same operation, using a transpericardial access to the descending thoracic aorta. In our opinion, the primary insertion of the CPS and the avoidance of an additional laparotomy in disk removal help promote the survival of such critically ill patients.
The objective of our study was to establish an animal model with extracorporeal circulation (ECC) for investigations on the long-term tolerability of different pericardial substitutes using the Goettingen minipig. A combination of halothane (0.4-0.6% vaporizer setting) in oxygen and nitrous oxide (FiO2 0.33), with the opioid piritramide (75 micrograms/kg/h i.v.) was used for anaesthesia. A muscle relaxant was not administered. Due to the size of the animals (mean body weight 37.6 kg) the operative procedure was the same as in humans. Specific changes preceding or following initiation of cardiopulmonary bypass (CPB), such as inactivation of the coagulation system (400 IU heparin/kg i.v.), haemodilution, and hypothermia (32 degrees C), did not result in any complication. We did not induce cardiac arrest during CPB in order to facilitate haemodynamic stability after weaning from CPB. In three animals a temporary increase in blood pressure occurred after protamine (2.5-3.0 mg/kg i.v.) was given to reverse the heparinization. Within 60 minutes after the end of surgery all animals could be extubated when spontaneous breathing and cough reflex were present. The postoperative follow-up period of nine months was uneventful apart from one animal which developed a superficial wound in the thoracic scar area. We conclude that our technique for ECC is a safe method allowing recovery and long-term follow-up after cardiac surgery in a porcine animal model.